<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319081</url>
  </required_header>
  <id_info>
    <org_study_id>JSA-ALI-2019-01</org_study_id>
    <secondary_id>2019/653</secondary_id>
    <nct_id>NCT04319081</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors</brief_title>
  <acronym>MEMOGAL</acronym>
  <official_title>Multicenter, Observational and Prospective Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors (MEMOGAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jose Seijas Amigo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinico Universitario de Santiago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective will be to evaluate the changes in the cognitive function in naive
      patients treated with PCSK9 inhibitors (Alirocumab and Evolocumab) by using the Montreal
      Cognitive Assesment questionnaire (MOCA).

      The secondary objectives will be: 1) To evaluate the levels of LDL-cholesterol changes from
      the beginning to the end of the study 2) To evaluate changes in Quality of Life among the
      EuroQol EQ-5D-3L questionnaire (it will also be associated to the cognitive function) 3)
      Assesment of direct costs in medications and outpatients consultations related with the
      health procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cognitive function</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>Assesment by Montreal Cognitive Assessment questionnaire (MOCA). Minimum value is 0 and maximum value is 30. A higher or equal value to 26 points will be considered normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol values</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>LDL-cholesterol changes will be assessed during the study by routine sample tests (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>By using the questionnaire called EuroQol EQ-5D-3L assessment. It has 2 parts, the first one has 5 questions with 3 possible answers (5 dimensions and 3 levels), so each health status has a rate called EVA from 1,0000 (the highest value) to - 0,5095 (the worst health status).
The second part is a visual self-assessment between 0 (the worst health status) and 100 (the best health status). https://euroqol.org/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct costs</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>Direct costs related with treatments and consultations (€)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>Total cholesterol evolution during the study in mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Lp(a)</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>Lp(a) evolution during the study in mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>24 to 36 months</time_frame>
    <description>€/QUALY</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Cognitive Function</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Uncontrolled patients with hypercholesterolemia</arm_group_label>
    <description>Patients that meet criteria inclusions and they have just started to take Alirocumab or Evolocumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCSK9 inhibitor</intervention_name>
    <description>Patients are included after PCSK9 inhibitors prescription , at the first dispensation</description>
    <arm_group_label>Uncontrolled patients with hypercholesterolemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with familial hypercholesterolemia (homozygous and heterozygous) and/or
        cardiovascular disease with LDL-cholestrol value &gt; 100 mg/dL and maximum statine doses or
        intolerance. With a first prescription of PCSK9 inhibitors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years old or over

          -  To start with the first funded dose of PCSK9 inhibitors ( LDL &gt; 100 mg/dL)

          -  Maximum dose or statin intolerance

        Exclusion Criteria:

          -  Diagnosis of any disease related with cognitive deterioration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Seijas Amigo, Pharmacist</last_name>
    <phone>981955764</phone>
    <email>jose.seijas.amigo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Virxen da Xunqueira de Cee</name>
      <address>
        <city>Cee</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Rodriguez Sanchez</last_name>
    </contact>
    <investigator>
      <last_name>Jose Luis Rodriguez Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arquiteto Marcide de Ferrol</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Casas Martinez</last_name>
    </contact>
    <investigator>
      <last_name>Antonia Casas Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Barbanza</name>
      <address>
        <city>Ribeira</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Mozo Peñalver</last_name>
    </contact>
    <investigator>
      <last_name>Hector Mozo Peñalver</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Espino Paisán</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Seijas Amigo, Pharmacist</last_name>
      <phone>+34981955764</phone>
      <email>jose.seijas.amigo@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Pedro Suarez Artime, Pharmacist</last_name>
      <email>pedro.suarez.artime@sergas.es</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Seijas Amigo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Suarez Artime</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego Rodriguez Penas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Ramon Gonzalez Juanatey</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Zarra Ferro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Público da Mariña de Burela</name>
      <address>
        <city>Burela</city>
        <state>Lugo</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concepción Castro Rubiños</last_name>
    </contact>
    <investigator>
      <last_name>Concepción Castro Rubiños</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Monforte</name>
      <address>
        <city>Monforte De Lemos</city>
        <state>Lugo</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Villaverde Piñeiro</last_name>
    </contact>
    <investigator>
      <last_name>Laura Villaverde Piñeiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital do Barco de Valdeorras</name>
      <address>
        <city>O Barco De Valdeorras</city>
        <state>Ourense</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Rodriguez Vazquez</last_name>
    </contact>
    <investigator>
      <last_name>Ana Rodriguez Vazquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Gayoso Rey</last_name>
    </contact>
    <investigator>
      <last_name>Monica Gayoso Rey</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karina Lorenzo Lorenzo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María del Mar Lopez-Gil Otero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Jose Mauriz Montero</last_name>
    </contact>
    <investigator>
      <last_name>María Jose Mauriz Montero</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Margusino Framiñan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus-Augusti de Lugo</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Perez Rodriguez</last_name>
    </contact>
    <investigator>
      <last_name>Natalia Perez Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Anido García</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Dominguez Guerra</last_name>
    </contact>
    <investigator>
      <last_name>María Dominguez Guerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Crespo Diz</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Crespo Diz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lara Gonzalez Freire</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1093/eurheartj/ehz746.0046</url>
    <description>Effect of PCSK9 inhibitors treatment on acute coronary syndrome and stroke incidence: a metanalysis of currently available clinical trials</description>
  </link>
  <reference>
    <citation>Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 Aug 17;377(7):633-643. doi: 10.1056/NEJMoa1701131.</citation>
    <PMID>28813214</PMID>
  </reference>
  <reference>
    <citation>Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.</citation>
    <PMID>30403574</PMID>
  </reference>
  <reference>
    <citation>Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.</citation>
    <PMID>28304224</PMID>
  </reference>
  <reference>
    <citation>Kołodziejczak M, Navarese EP. Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature. Atherosclerosis. 2016 Apr;247:189-92. doi: 10.1016/j.atherosclerosis.2016.02.011. Epub 2016 Feb 15. Review.</citation>
    <PMID>26926598</PMID>
  </reference>
  <reference>
    <citation>Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, Torguson R, Brewer HB Jr, Waksman R. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016 Feb 7;37(6):536-45. doi: 10.1093/eurheartj/ehv563. Epub 2015 Nov 17. Review.</citation>
    <PMID>26578202</PMID>
  </reference>
  <reference>
    <citation>Shibata N, Ohnuma T, Higashi S, Higashi M, Usui C, Ohkubo T, Watanabe T, Kawashima R, Kitajima A, Ueki A, Nagao M, Arai H. No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients. Psychiatr Genet. 2005 Dec;15(4):239.</citation>
    <PMID>16314752</PMID>
  </reference>
  <reference>
    <citation>Xue-Shan Z, Juan P, Qi W, Zhong R, Li-Hong P, Zhi-Han T, Zhi-Sheng J, Gui-Xue W, Lu-Shan L. Imbalanced cholesterol metabolism in Alzheimer's disease. Clin Chim Acta. 2016 May 1;456:107-114. doi: 10.1016/j.cca.2016.02.024. Epub 2016 Mar 2. Review.</citation>
    <PMID>26944571</PMID>
  </reference>
  <reference>
    <citation>Banach M, Rizzo M, Nikolic D, Howard G, Howard V, Mikhailidis D. Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol Ther. 2017 Feb;170:181-191. doi: 10.1016/j.pharmthera.2016.11.001. Epub 2016 Nov 16. Review.</citation>
    <PMID>27865998</PMID>
  </reference>
  <reference>
    <citation>Paquette M, Saavedra YGL, Poirier J, Théroux L, Dea D, Baass A, Dufour R. Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease. J Geriatr Psychiatry Neurol. 2018 Mar;31(2):90-96. doi: 10.1177/0891988718764330. Epub 2018 Mar 21.</citation>
    <PMID>29562810</PMID>
  </reference>
  <reference>
    <citation>Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, Miller K, Kastelein JJ. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. J Am Coll Cardiol. 2017 Feb 7;69(5):471-482. doi: 10.1016/j.jacc.2016.11.037.</citation>
    <PMID>28153102</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinico Universitario de Santiago</investigator_affiliation>
    <investigator_full_name>Jose Seijas Amigo</investigator_full_name>
    <investigator_title>Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Cognitive Function</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Pharmacoeconomics</keyword>
  <keyword>PCSK9 inhibitors</keyword>
  <keyword>Alirocumab</keyword>
  <keyword>Evolocumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

